Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know
Baxter’s Q3 showed a mixed picture. Revenue from continuing operations rose about 5% year-over-year to $2.84 billion, helped by strong performance in its Pharmaceuticals and Healthcare Systems unitsbaxter.combaxter.com. However, sales fell short of the street’s ~$2.88 billion estimatereuters.com. On profit, Baxter earned an adjusted $0.69 per share, well above the ~$0.60 expectedreuters.comchartmill.com.
